DeepCura

AlloArc Endocrinology Note (Standard)

Version 1 · Updated November 18, 2026

About this template

Use this template when: any outpatient endocrinology visit, new or follow-up, including post-hospital visits, for diabetes and diabetes technology, thyroid, bone, metabolic, weight, pituitary, adrenal or hormone care. Writes Chief Complaints, HPI, ROS, Assessment with ICD-10 codes and a plan per code, formatted for any EHR. Designed to document only what the visit and chart support. No physical exam or orders.

Sample note

Sample note · Written by the author · Screened for PHI

Chief Complaints:
Follow-up.
Nausea

HPI:
54-year-old male with a past medical history of type 2 diabetes mellitus and hyperlipidemia, presents to endocrinology for diabetes follow-up. The patient also reports nausea.

1. TYPE 2 DIABETES MELLITUS:
- Nausea since semaglutide (Ozempic) was increased from 0.5 mg to 1 mg subcutaneously once weekly on 08/10/2026, occurring the 2 days after the Sunday-night injection and leading him to skip lunch on a couple of Mondays; worst during the first 2 weeks of August 2026 and has eased since. Denies vomiting or abdominal pain; bowel movements approximately every other day.
- Takes metformin ER 1000 mg twice daily; misses the evening dose approximately twice weekly.
- Fasting home glucose 130-150 on most mornings, with one reading of 118; denies shakiness, sweating, or readings under 70. Denies numbness, burning, or tingling in the feet.
- A1c 7.9% point-of-care 10/05/2026 (8.6% 06/22/2026, 9.1% 03/16/2026). Weight 104.3 kg 10/05/2026 (107.5 kg 06/22/2026).
- Had a dilated eye examination in April 2026 and was told it was normal.

2. HYPERLIPIDEMIA:
- On atorvastatin 40 mg nightly without muscle aching or weakness. LDL 88 mg/dL (06/22/2026).

Review of Systems:
Gastrointestinal: Reports nausea and less frequent bowel movements. Denies vomiting or abdominal pain.
Musculoskeletal: Denies muscle aching or weakness.
Neurological: Denies numbness, burning, or tingling in the feet.
Endocrine: Denies shakiness or sweating.

Assessment:
ICD E11.65-Type 2 diabetes mellitus with hyperglycemia:
ICD E78.5-Hyperlipidemia, unspecified:

Treatment/Plan:
ICD E11.65-Type 2 diabetes mellitus with hyperglycemia:
- A1c 7.9% point-of-care today with a goal under 7%; continued semaglutide 1 mg subcutaneously once weekly without a dose increase while nausea from the last increase settles.
- Plan to increase semaglutide to 2 mg weekly at the next visit if nausea has resolved and A1c remains 7% or higher.
- Counseled on smaller meals on Mondays and Tuesdays and stopping eating when full.
- Advised holding the next semaglutide dose and calling the clinic for vomiting, inability to keep fluids down, or severe abdominal pain.
- Refilled metformin ER 1000 mg twice daily; advised keeping the evening tablets next to the toothbrush.
- Ordered A1c and urine albumin-to-creatinine ratio to be drawn the week before the next visit.
- Requested records of the April 2026 dilated eye examination.
- Follow-up in January 2027.
- Prior studies: Urine albumin-to-creatinine ratio 18 mg/g and creatinine 0.9 mg/dL with eGFR 96 (06/22/2026).

ICD E78.5-Hyperlipidemia, unspecified:
- LDL 88 mg/dL (06/22/2026); increased atorvastatin from 40 mg to 80 mg nightly for a goal LDL under 70 given diabetes.
- Advised the patient to report new muscle aching or weakness without another explanation.
- Ordered fasting lipid panel to be drawn the week before the next visit.

This sample note was written by the template’s author and screened for patient information before publishing. Actual output may vary depending on patient encounter and clinical context.